132
Participants
Start Date
August 31, 2012
Primary Completion Date
August 31, 2013
Study Completion Date
August 31, 2013
BIIB041 (PR Fampridine)
10 mg twice daily, given orally. Doses of study treatment must be spaced at least 12 hours apart. If a dose of study treatment is delayed or missed, the participant should not dose again until their next scheduled dose. Tablets must be swallowed whole and should be taken without food.
Placebo
Twice daily, given orally. Doses of study treatment must be spaced at least 12 hours apart. If a dose of study treatment is delayed or missed, the participant should not dose again until their next scheduled dose. Tablets must be swallowed whole and should be taken without food.
Research Site, Ath
Research Site, Bruges
Research Site, Brussels
Research Site, Leuven
Research Site, Yvoir
Research Site, Halifax
Research Site, London
Research Site, Gatineau
Research Site, Greenfield Park
Research Site, Montreal
Research Site, Ancona
Research Site, Brescia
Research Site, Empoli
Research Site, Palermo
Research Site, Roma
Research Site, Breda
Research Site, Sittard-Geleen
Research Site, Gothenburg
Research Site, Stockholm
Research Site, Edgbaston
Research Site, Poole
Research Site, Swansea
Research Site, London
Lead Sponsor
Biogen
INDUSTRY